

CRIPTO (TDGF1) Antibody (N-term) Blocking peptide
Synthetic peptide
Catalog # BP2047a**Specification**

CRIPTO (TDGF1) Antibody (N-term) Blocking peptide - Product InformationPrimary Accession [P13385](#)**CRIPTO (TDGF1) Antibody (N-term) Blocking peptide - Additional Information****Gene ID** 6997**Other Names**

Teratocarcinoma-derived growth factor 1, Cripto-1 growth factor, CRGF, Epidermal growth factor-like cripto protein CR1, TDGF1, CRIPTO

Target/Specificity

The synthetic peptide sequence used to generate the antibody [AP2047a](/product/products/AP2047a) was selected from the N-term region of human TDGF1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

CRIPTO (TDGF1) Antibody (N-term) Blocking peptide - Protein Information**Name** CRIPTO {ECO:0000303|PubMed:2792079, ECO:0000312|HGNC:HGNC:11701}**Function**

GPI-anchored cell membrane protein involved in Nodal signaling. Cell-associated CRIPTO acts as a Nodal coreceptor in cis. Shedding of CRIPTO by TMEM8A modulates Nodal signaling by allowing soluble CRIPTO to act as a Nodal coreceptor on other cells (PubMed: [27881714](http://www.uniprot.org/citations/27881714)). Could play a role in the determination of the epiblastic cells that subsequently give rise to the mesoderm (PubMed: [11909953](http://www.uniprot.org/citations/11909953)).

Cellular Location

Cell membrane; Lipid-anchor, GPI-anchor. Secreted. Note=Released from the cell membrane by GPI cleavage.

Tissue Location

Preferentially expressed in gastric and colorectal carcinomas than in their normal counterparts.
Expressed in breast and lung.

CRIPTO (TDGF1) Antibody (N-term) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

CRIPTO (TDGF1) Antibody (N-term) Blocking peptide - Images**CRIPTO (TDGF1) Antibody (N-term) Blocking peptide - Background**

TDGF1 is expressed both in ES cells and during the early phases of embryo development, while in adults it is reactivated in a wide range of epithelial cancers. This protein could play a role in the determination of the epiblastic cells that subsequently give rise to the mesoderm. It is preferentially expressed in gastric and colorectal carcinomas compared to their normal counterparts.

CRIPTO (TDGF1) Antibody (N-term) Blocking peptide - References

Parisi, S., et al., J. Cell Biol. 163(2):303-314 (2003).Gray, P.C., et al., Proc. Natl. Acad. Sci. U.S.A. 100(9):5193-5198 (2003).Yan, Y.T., et al., Mol. Cell. Biol. 22(13):4439-4449 (2002).de la Cruz, J.M., et al., Hum. Genet. 110(5):422-428 (2002).Dono, R., et al., Am. J. Hum. Genet. 49(3):555-565 (1991).